Eylea FDA Approval History
FDA Approved: Yes (First approved November 18, 2011)
Brand name: Eylea
Generic name: aflibercept
Dosage form: Injection
Company: Regeneron Pharmaceuticals, Inc.
Treatment for: Macular Degeneration, Macular Edema, Diabetic Retinopathy
Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Development Timeline for Eylea
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.